KalVista Pharmaceuticals (4XC1) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4XC1 Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

KalVista

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4XC1 Stock 12 Month Forecast

Average Price Target

€30.46

▲(107.22% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for KalVista Pharmaceuticals in the last 3 months. The average price target is €30.46 with a high forecast of €33.82 and a low forecast of €25.15. The average price target represents a 107.22% change from the last price of €14.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"€8","21":"€21","34":"€34","14.5":"€14.5","27.5":"€27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33.81726699,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€33.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.4615535733,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€30.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.14617289,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€25.15</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,14.5,21,27.5,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.4,14.97055899923077,16.541117998461537,18.111676997692307,19.682235996923076,21.252794996153845,22.823353995384615,24.393912994615384,25.964471993846153,27.535030993076923,29.105589992307692,30.67614899153846,32.24670799076923,{"y":33.81726699,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.4,14.712427197946155,16.02485439589231,17.337281593838462,18.64970879178462,19.962135989730772,21.274563187676925,22.586990385623082,23.89941758356923,25.21184478151539,26.524271979461542,27.836699177407695,29.149126375353852,{"y":30.4615535733,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.4,14.303551760769231,15.207103521538462,16.110655282307693,17.014207043076922,17.917758803846155,18.821310564615384,19.724862325384613,20.628414086153846,21.53196584692308,22.435517607692308,23.339069368461537,24.24262112923077,{"y":25.14617289,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.1,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.3,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€33.82

Average Price Target€30.46

Lowest Price Target€25.15

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Fein

H.C. Wainwright

€32.32

Buy

119.85%

Upside

Reiterated

03/12/26

Early Outperformance and Expanding On‑Demand HAE Opportunity Justify Buy Rating on KalVista

Debanjana Chatterjee

JonesTrading

€32.32→€34.06

Buy

131.73%

Upside

Reiterated

02/19/26

Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (NASDAQ: KALV), Bausch Health Companies (NYSE: BHC) and Insulet (NASDAQ: PODD)

Stacy Ku

TD Cowen

€26.2→€30.57

Buy

107.96%

Upside

Reiterated

01/29/26

Analysts Are Bullish on Top Healthcare Stocks: KalVista Pharmaceuticals (KALV), Mirum Pharmaceuticals (MIRM)

Tazeen Ahmad

Bank of America Securities

€26.2→€27.95

Buy

90.14%

Upside

Reiterated

01/27/26

Bank of America Securities Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)

Jonathan Wolleben

Citizens JMP

€24.46→€25.33

Buy

72.31%

Upside

Reiterated

01/09/26

KalVista price target raised to $29 from $28 at CitizensKalVista price target raised to $29 from $28 at Citizens

Paul Matteis

Stifel Nicolaus

€34.06

Buy

131.73%

Upside

Reiterated

01/09/26

Stifel Nicolaus Sticks to Their Buy Rating for KalVista Pharmaceuticals (KALV)

Serge Belanger

Needham

€27.95

Buy

90.14%

Upside

Reiterated

01/09/26

KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating

Maury Raycroft

Jefferies

€33.19

Buy

125.79%

Upside

Reiterated

01/09/26

KalVista Pharmaceuticals (KALV) Gets a Buy from Jefferies

Joseph Schwartz

Leerink Partners

―

Buy

―

Reiterated

10/15/25

Charles Duncan

Cantor Fitzgerald

―

Buy

―

Reiterated

03/26/25

Cantor Fitzgerald reiterates Overweight Rating on Kalvista Pharmaceuticals Inc (KALV)Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Fein

H.C. Wainwright

€32.32

Buy

119.85%

Upside

Reiterated

03/12/26

Early Outperformance and Expanding On‑Demand HAE Opportunity Justify Buy Rating on KalVista

Debanjana Chatterjee

JonesTrading

€32.32→€34.06

Buy

131.73%

Upside

Reiterated

02/19/26

Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (NASDAQ: KALV), Bausch Health Companies (NYSE: BHC) and Insulet (NASDAQ: PODD)

Stacy Ku

TD Cowen

€26.2→€30.57

Buy

107.96%

Upside

Reiterated

01/29/26

Analysts Are Bullish on Top Healthcare Stocks: KalVista Pharmaceuticals (KALV), Mirum Pharmaceuticals (MIRM)

Tazeen Ahmad

Bank of America Securities

€26.2→€27.95

Buy

90.14%

Upside

Reiterated

01/27/26

Bank of America Securities Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)

Jonathan Wolleben

Citizens JMP

€24.46→€25.33

Buy

72.31%

Upside

Reiterated

01/09/26

KalVista price target raised to $29 from $28 at CitizensKalVista price target raised to $29 from $28 at Citizens

Paul Matteis

Stifel Nicolaus

€34.06

Buy

131.73%

Upside

Reiterated

01/09/26

Stifel Nicolaus Sticks to Their Buy Rating for KalVista Pharmaceuticals (KALV)

Serge Belanger

Needham

€27.95

Buy

90.14%

Upside

Reiterated

01/09/26

KalVista (Ekterly) Upgraded as 2026 Top Idea: De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised $32 Target Support Buy Rating

Maury Raycroft

Jefferies

€33.19

Buy

125.79%

Upside

Reiterated

01/09/26

KalVista Pharmaceuticals (KALV) Gets a Buy from Jefferies

Joseph Schwartz

Leerink Partners

―

Buy

―

Reiterated

10/15/25

Charles Duncan

Cantor Fitzgerald

―

Buy

―

Reiterated

03/26/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering KalVista Pharmaceuticals

3 Months

xxx

Success Rate

14/23 ratings generated profit

Average Return

+12.60%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +12.60% per trade.

1 Year

Joseph SchwartzLeerink Partners

Success Rate

20/23 ratings generated profit

Average Return

+28.50%

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +28.50% per trade.

2 Years

xxx

Success Rate

22/23 ratings generated profit

Average Return

+43.89%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.65% of your transactions generating a profit, with an average return of +43.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4XC1 Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4XC1 has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 4XC1 average Analyst price target in the past 3 months is 30.46.

Each month's total comprises the sum of three months' worth of ratings.

4XC1 Financial Forecast

4XC1 Earnings Forecast

The previous quarter’s earnings for 4XC1 were -€0.80.

4XC1 Sales Forecast

Currently, no sales data available.

4XC1 Stock Forecast FAQ

What is DE:4XC1’s average 12-month price target, according to analysts?

Based on analyst ratings, KalVista Pharmaceuticals, Inc.’s 12-month average price target is 30.46.

What is DE:4XC1’s upside potential, based on the analysts’ average price target?

KalVista Pharmaceuticals, Inc. has 107.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KalVista Pharmaceuticals, Inc. a Buy, Sell or Hold?

KalVista Pharmaceuticals, Inc. has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is KalVista Pharmaceuticals, Inc.’s share price target?

The average share price target for KalVista Pharmaceuticals, Inc. is 30.46. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €33.82 ,and the lowest forecast is €25.15. The average share price target represents 107.22% Increase from the current price of €14.7.

What do analysts say about KalVista Pharmaceuticals, Inc.?

KalVista Pharmaceuticals, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of KalVista Pharmaceuticals, Inc.?

To buy shares of DE:4XC1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

KalVista Pharmaceuticals (4XC1) Stock Forecast & Price Target

4XC1 Analyst Ratings

4XC1 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering KalVista Pharmaceuticals

4XC1 Analyst Recommendation Trends

4XC1 Financial Forecast

4XC1 Earnings Forecast

4XC1 Sales Forecast

4XC1 Stock Forecast FAQ

Detailed List of Analyst Forecasts